Gerrard G E, Dodwell D J, Vail A, Watters J, Overend M A
Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, UK.
Clin Oncol (R Coll Radiol). 1996;8(1):39-42. doi: 10.1016/s0936-6555(05)80037-8.
A protocol was designed to help junior doctors to manage patients with malignant hypercalcaemia (MH). Seventy-five patients received 30 mg, 60 mg or 90 mg doses of pamidronate, depending on their initial serum calcium level. Fifty-four (72%) patients achieved normocalcaemia (NC) within 5 days after a single infusion of pamidronate. A further ten (13%) patients reached NC after a second dose, and 11 (15%) remained hypercalcaemic until death. NC was maintained for a median duration of 24 days. Patients received, on average, 30 mg less pamidronate than that given in the manufacturer's dosing schedule. The protocol was considered effective, economical and practical in the routine management of MH.
设计了一项方案以帮助初级医生管理恶性高钙血症（MH）患者。75名患者根据其初始血清钙水平接受了30毫克、60毫克或90毫克剂量的帕米膦酸盐。54名（72%）患者在单次输注帕米膦酸盐后5天内实现了血钙正常（NC）。另有10名（13%）患者在第二次给药后达到NC，11名（15%）患者直至死亡一直处于高钙血症状态。NC维持的中位持续时间为24天。患者平均接受的帕米膦酸盐比制造商给药方案中规定的剂量少30毫克。该方案在MH的常规管理中被认为是有效、经济且实用的。
